About Us
Our Leadership
Our Science
News
Contact Us
About Us
Our Leadership
Our Science
News
Contact Us
Press Release
MEDIA COVERAGE
Press Releases
Articles
PRESENTATIONS
Events
View All
Press Release
Oct 27, 2026 |
ProJenX to Present Data Update for the Prosetin Development Program at the 2026 NEALS Annual Meeting
Read More
Press Release
Jun 16, 2026 |
ProJenX Announces a Development Update for Prosetin, a First-in-Class, CNS-Penetrant MAP4K Inhibitor
Read More
Press Release
Sep 26, 2024 |
ProJenX and Unlearn Announce Partnership to Augment ALS Clinical Trial PRO-101 with Digital Twin Model
Read More
Press Release
Aug 27, 2024 |
ProJenX Announces Formation of Clinical Advisory Board
Read More
Press Release
Jun 20, 2024 |
ProJenX Announces Receipt of $1M Hoffman ALS Clinical Trial Award from the ALS Association
Read More
Press Release
Mar 28, 2024 |
ProJenX Announces Removal of Partial Clinical Hold for Prosetin Program by FDA
Read More
Press Release
Feb 14, 2024 |
ProJenX Receives European Authorization for First Study of Prosetin in People Living with ALS
Read More
Press Release
Nov 29, 2023 |
ProJenX Receives Health Canada Clinical Trial Application Authorization for First Study of Prosetin in People Living with ALS
Read More
Press Release
Nov 2, 2023 |
ProJenX Announces Initial Closing of $15M Series A Financing and Appoints Rick Hartz to Board of Directors
Read More
Press Release
Mar 30, 2023 |
ProJenX Announces Formation of Scientific Advisory Board
Read More
Press Release
May 18, 2022 | ProJenX
ProJenX Names Life Sciences Industry Veteran Stan E. Abel as CEO
Read More
Press Release
Mar 1, 2022 | ProJenX
ProJenX Announces First Person Dosed in Phase 1 Study of Prosetin
Read More
Next Page
Contact Us to Learn More About Our Fight Against ALS
Contact Us
